Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Bulent Undar"'
Autor:
Süleyman Cem Adıyaman, İnci Alacacıoğlu, Ayça Ersen Danyeli, Doğuş Türkyılmaz, Ömür Gökmen Sevindik, Fatih Demirkan, Özden Pişkin, Mehmet Ali Özcan, Bülent Ündar, Şermin Özkal, Güner Hayri Özsan
Publikováno v:
Turkish Journal of Hematology, Vol 36, Iss 2, Pp 81-87 (2019)
Objective: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). The treatment of older NHL patients has always been a struggle; however, treatment statistics have begun showing favorable results similar to thos
Externí odkaz:
https://doaj.org/article/a052bd3670754c85b2d726bbebae4be3
Autor:
Şerife Solmaz Medeni, Doğus Türkyılmaz, Celal Acar, Ömür Gökmen Sevindik, Faize Yüksel, Özden Pişkin, Mehmet Ali Özcan, Fatih Demirkan, Bülent Ündar, İnci Alacacıoğlu, Güner Hayri Özsan
Publikováno v:
Turkish Journal of Hematology, Vol 35, Iss 4, Pp 271-276 (2018)
Objective: High-doses of melphalan treatment with autologous stem cell transplantation in multiple myeloma (MM) remains a major treatment modality in suitable patients. A minimal dose of 2x106/kg CD34+ cells is preferred to achieve engraftment. Some
Externí odkaz:
https://doaj.org/article/3903f33454c340b9bbc990d2d2e4c0d0
Autor:
Nurhilal Büyükkurt, Mehmet Ali Özcan, Ülkü Ergene, Bahriye Payzın, Sunay Tunalı, Fatih Demirkan, Hayri Özsan, Özden Pişkin, Bülent Ündar
Publikováno v:
Turkish Journal of Hematology, Vol 32, Iss 2, Pp 152-157 (2015)
INTRODUCTION: The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab (R) era. The aim of this study was to examine the FcγRIIIA gene polymorphism distribution of DLBCL patients who had been t
Externí odkaz:
https://doaj.org/article/9ad2891c01344f109b1f73dd73d0a6a7
Publikováno v:
Turkish Journal of Hematology, Vol 28, Iss 02, Pp 146-148 (2011)
Externí odkaz:
https://doaj.org/article/07857b87a25d43b6af298c69d11e34f4
Autor:
Serife Solmaz, Ozcan Uzun, Celal Acar, Omur Gokmen Sevindik, Ozden Piskin, Hayri Guner Ozsan, Fatih Demirkan, Bulent Undar, Ahmet Alacacioglu, Mehmet Ali Ozcan, Inci Alacacioglu
Publikováno v:
Journal of Laboratory Physicians, Vol 10, Iss 04, Pp 363-369 (2018)
BACKGROUND: Recent reports showed neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. M
Externí odkaz:
https://doaj.org/article/9614468517bc47dc9a3cff5ebe6f7c96
Autor:
Inci Alacacioglu, Aydanur Kargi, Mehmet Ali Ozcan, Ozden Piskin, Cilem Solak, Mustafa Secil, Mehtat Unlu, Fatih Demirkan, Guner Hayri Ozsan, Bulent Undar
Publikováno v:
Brazilian Journal of Infectious Diseases, Vol 13, Iss 3, Pp 238-241
A patient with mantle cell non-Hodgkin's lymphoma presented herself with fever, nausea, right upper quadrant pain on the 7th day of R-CHOP chemotherapy. After hospitalization with the suspicion of acute cholecystitis, she received antibiotherapy with
Externí odkaz:
https://doaj.org/article/d382130da30d40d08a8044ef2ced0d92
Autor:
Bernardo Garichochea, Judit Demeter, Yuankai Shi, Umberto Vitolo, Enrica Morra, Margarida Marques, Miklos Egyed, Toshiki Uchida, Árpád Illés, Kenichi Ishizawa, Cristina Ligia Cebotaru, Ashis Mukhopadhyay, Masafumi Taniwaki, Sung-Soo Yoon, Cristina-Ligia Truica, Cheol Won Suh, Irina Lysenko, Naokuni Uike, Huaqing Wang, Achiel Van Hoof, Maryna Kyselyova, Osmanov Ea, Andrew Belch, Alexy Kuzmin, Caballero Gabarrón, Steven Van Steenweghen, Sergio Cancelado, Olga Samoilova, Kensei Tobinai, Kiyoshi Ando, Susumu Nakahara, Tatiana Scheider, Massimo Federico, Dmitry Udovitsa, Xiaoyan Ke, Yurii Lorie, Tatsu Shimoyama, Weerasak Nawarawong, Sebastian Grosicki, Gregor Verhoef, Nuriet Khuageva, Suporn Chuncharune, Fritz Offner, Albert Oriol Rocafiguera, Charles Farber, Ernst Späth-Schwalbe, Juliana Pereira, Ting Liu, Lee-Yung Shih, Steven Le Gouill, Miklos Udvardy, Richard Greil, Carmen Cao, Tomohiro Kinoshita, Horia Bumbea, Yasuhito Terui, Eva Gonzalez-Barca, Irina Bulavina, Peter Hu, Francisco Javier Capote, Olga Serduk, Akihiro Tomita, Ilseung Choi, Mahmut Gumus, Udomsak Bunworasate, Adriana Teixeira, Vladimir Merkulov, Yeow Tee Goh, Tadeusz Robak, Huiqiang Huang, Jie Jin, Cristina Ileana Burcoveanu, Halyna Pylypenko, Joaquín Díaz, Herlander Marques, Zoltán Gasztonyi, Vijay Rao Phooshkooru, Gayane Tumyan, Maike De Wit, Ali Khojasteh, Marcelo Capra, Vladimir Lima, Dai Maruyama, Viacheslav Pavlov, Georg Heß, Carmino Antonio De Souza, Zhao Wang, Iryna Kryachok, Amel Mezlini, Galvez Cardenas, Marina Golubeva, Lyudmila Kuzina, Patricia Santi, Remy Gressin, Balkis Meddeb, Xiaonan Hong, David Belada, Bernard De Prijck, Jan Maciej Zaucha, Jiri Mayer, Michinori Ogura, Rumiko Okamoto, Dolores, Irit Avivi, Mario Ojeda-Uribe, Grigoriy B Rekhtman, Jun Zhu, Reyes Arranz, Polina Kaplan, André Bosly, Ann Van De Velde, Kenny Mauricio, Yuri Dunaev, Anatoly Golenkov, Oleg Gladkov, Yoshiharu Maeda, Franco Cavalli, Dina Ben Yehuda, Michele Baccarani, Markus Raderer, Razvan Stoia, Carlos Appiani, Zvenyslava Masliak, Zita Borbenyi, Guiseppe Rossi, Julia Alexeeva, Johannes Drach, Kateryna Vilchevskaya, Georgii Manikhas, Jan Novák, Noppadol Siritanaratkul, Zhixiang Shen, Alexander Suvorov, Michael Crump, Pierre Zachee, Ofer Shpilberg, Sepideh Nemat, Mitsutoshi Kurosawa, Sreejith Nair, Bulent Undar, Govind Babu, Kudrat Abdulkadryrov, Adriana Sheliga
Publikováno v:
The Lancet Oncology. 19:1449-1458
Summary Background In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were c
Autor:
Serife Solmaz, Celal Acar, Ahmet Seyhanlı, Omur Gokmen Sevindik, Ozden Piskin, Mehmet Ali Ozcan, Fatih Demirkan, Bülent Undar, Inci Alacacioglu, Guner Hayri Ozsan
Publikováno v:
Indian Journal of Transplantation, Vol 14, Iss 1, Pp 57-62 (2020)
Introduction: High-dose chemotherapy (HDC) and autologous stem cell transplantation(ASCT) still remains in the treatment of myeloma patients even during the period of new agents. Materials and Methods: We analysed the prognostic affect of pretranspla
Externí odkaz:
https://doaj.org/article/d3fc096c721d4ec1a3550a2022a31539
Autor:
Guray Saydam, Ibrahim C. Haznedaroglu, Leylagul Kaynar, Akif S. Yavuz, Ridvan Ali, Birol Guvenc, Olga M. Akay, Zafer Baslar, Ugur Ozbek, Mehmet Sonmez, Demet Aydin, Mustafa Pehlivan, Bulent Undar, Simten Dagdas, Orhan M. Ayyildiz, Diyar Z. Akkaynak, Ilkiz M. Dag, Osman Ilhan
Publikováno v:
Blood. 122:2742-2742
Introduction Nilotinib, a more potent and selective drug than imatinib, was approved by the FDA and EMA initially for the treatment of chronic and accelerated phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) patients re
Autor:
Nurhilal Büyükkurt, Guner Hayri Özsan, Sermin Özkal, Gülşah Seydaoğlu, İnci Alacacıoğlu, Mehmet Ali Özcan, Fatih Demirkan, Özden Pişkin, Bülent Ündar
Publikováno v:
Cukurova Medical Journal, Vol 42, Iss 3, Pp 499-506 (2017)
Amaç: Birçok faktör hematopoetik kök hücre (HKH) engraftmanını etkiler. Bu çalışmada hematolojik kanseri olan hastalarda kemik iliğindeki myelofibrozis ve anjiogenezisin engraftman üzerine etkisi araştırılmıştır.Gereç ve Yöntem: O
Externí odkaz:
https://doaj.org/article/469bcc27f93e431aafcbf932258c804b